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1
Patient awareness and approval for an opt-out 
genomic biorepository
A value core to all modern statements on the 
ethics of human research is that participation 
in research should be fully voluntary [1–3]. In 
practice, the value of voluntariness is often asso-
ciated with the assumption of risk. For exam-
ple, US regulations on research with human 
subjects require that participants be provided 
with detailed information on relevant risks and 
benefits, and signal their willingness to take on 
risk by signing an informed consent document. 
Researchers conducting studies involving very 
limited risks (such as epidemiological research 
using existing data) need not seek written 
consent.
There are, however, other reasons to ensure 
that participation in research is voluntary. The 
principle of respect for persons, in particular, 
implies that the wishes of humans contributing 
samples and data should be respected even when 
they are not engaging in research as human 
subjects [4]. Failure to show this form of respect 
threatens public support for research [5]. We have 
previously coined the term ‘human nonsubjects 
research’ to highlight the respect that is due to 
persons who donate samples for research, even 
when those persons are not engaged in research 
as research subjects [6,7]. 
The availability of new technologies such as 
next-generation sequencing and advanced com-
putational approaches create opportunities to 
conduct research in new ways, which in turn 
create the need to re-examine how voluntary 
participation can be obtained within the scope of 
existing research regulations and ethical values. 
Recent innovations, for example, have made it 
possible to generate useful health-related find-
ings using large data sets that contain medical 
record data and biosamples. These collections 
may be referred to as biorepositories or bio-
banks. This type of research can be conducted 
using only de-identified data and thus may be 
considered to involve risk similar to epidemio-
logical research. In fact, US human research 
protections regulations define research on de-
identified information and biosamples from 
humans as exempt from the requirements of the 
Common Rule, including those for informed 
consent [101]. These regulations do not require 
complete anonymization of information. Indeed, 
it may not even be possible to obtain complete 
anonymization [8,9]. Current regulations instead 
provide guidance on the information that must 
be removed or altered in order for data to be 
considered deidentified [102]. 
Given that written informed consent may not 
be required by regulations, but that respect for 
research participants remains important, several 
institutions have begun to explore whether opt-
in and opt-out approaches can be used effectively 
to obtain permission from participants to use 
their medical record information and leftover 
biosamples for biorepository research [10,11]. 
Opt-in and opt-out methods are designed to 
minimize the burdens of eliciting voluntary par-
ticipation from a large number of patients while 
providing those who do not wish to contribute 
the opportunity to exercise that preference. Such 
opportunities for participants to have a say are 
especially important in research involving next-
generation sequencing, since some patients will 
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have concerns about the private or potentially 
stigmatizing information that may be revealed 
through sequencing technologies.
Unlike informed consent methods, opt-in and 
opt-out approaches assume that any decision not 
to participate is likely to be based on a patient’s 
general disposition toward the idea of research on 
their biosamples and that participants can usu-
ally make this decision with a simple overview 
of what is involved in the research. The primary 
aim is to ensure that any decisions about partici-
pation or nonparticipation authentically reflect a 
person’s preferences. Comprehensive information 
about the research is not always needed to attain 
that end. It has been argued that providing com-
prehensive information to research participants 
is more relevant to the aim of protection against 
liability and that providing participants with 
relatively brief information about research stud-
ies may actually improve their ability to make 
effective decisions [12]. In this spirit, opt-in and 
opt-out documents are usually provided as short 
permission forms focused on notifying patients 
that samples are being collected for research and 
that patients have a choice about whether their 
sample will be included.
If opt-in or opt-out approaches are to be con-
sidered as suitable alternatives to obtaining writ-
ten informed consent, the forms and other noti-
fication efforts they utilize must be effective with 
respect to making potential participants aware 
of the research and providing them with enough 
information to make an effective decision. Since 
the default for opt-out methods is inclusion in 
research, biorepositories utilizing this approach 
must additionally ensure that participants rec-
ognize that they have the opportunity to opt-out 
of participation.
In this article we report the findings of an 
exit interview study conducted with patients at 
Vanderbilt University Medical Center (TN, USA) 
on BioVU, an opt-out biorepository composed of 
leftover clinical blood samples and de-identified 
medical record information. At the time this study 
was conducted, patients were asked to sign a two-
page ‘consent for treatment’ form at the time of 
their first visit to an outpatient clinic and then 
once every 12 months. A description of BioVU 
along with an opt-out checkbox were included 
in this “consent for treatment” form just above 
the signature line. Patients wishing to opt-out 
of inclusion of their biosample in BioVU were 
prompted to check the box indicating this prefer-
ence. The language used in this form is provided 
in Supplementary Figure 1a (see online www.future-
medicine.com/doi/suppl/10.2217/PME.13.34). 
Through this form, all patients receiving care at 
a Vanderbilt outpatient facility were notified of 
BioVU and their opportunity to opt-out. In order 
to supplement this form, patients were also noti-
fied of BioVU through posters and pamphlets in 
clinical areas, and advertisements in local publi-
cations. The interview study reported here was 
intended to evaluate whether the procedures 
adopted by BioVU were adequate in terms of 
informing patients of this research and making 
them aware that opportunities to opt-out are pro-
vided. We explore here the implications of these 
findings for the policies that should be adopted by 
individual opt-out bio repositories, as well as their 
implications for the larger debate on alternative 




From 2009 to 2012, we conducted exit inter-
views with adult patients and parents of pediatric 
patients who were having their blood drawn at 
outpatient phlebotomy areas. This study involved 
three distinct cohorts. First, we conducted inter-
views in 2009 with adult patients having blood 
drawn at the two busiest adult outpatient phle-
botomy areas in Vanderbilt University Medical 
Center (Adult time point 1 or Adult 1 cohort). 
During this period, the biorepository was rela-
tively new and collected samples from adult 
patients only. In 2010, immediately following 
expansion of the biorepository to include pedi-
atric patients, we began interviewing the parents 
of pediatric patients who were having their blood 
drawn at the two busiest outpatient phlebotomy 
areas in the Monroe Carell Jr. Children’s Hos-
pital at Vanderbilt (Nashville, TN, USA; Pedi-
atric cohort [Peds cohort]). Finally, in 2011, we 
began a second round of exit interviews at the 
same adult phlebotomy areas where the Adult 1 
cohort sample was collected. This second sample 
was obtained to determine whether awareness 
and approval for the opt-out biorepository had 
changed as the biorepository became better estab-
lished and public notification efforts continued 
(Adult time point 2 or Adult 2 cohort).
No identifiable information about respon-
dents was viewed or recorded at any time. The 
Vanderbilt Institutional Review Board reviewed 
this study and approved its classification as an 
exempt study.
n Survey design
The survey instruments used for each of the 
three cohorts were similar. The instrument 
Personalized Medicine (2013) 10 (4)350 future science group
Patient awareness & approval for an opt-out genomic biorepository ReseaRch aRticle
used for the Adult 1 cohort was designed col-
laboratively by two pediatricians with expertise 
in research ethics issues (KB Brothers and EW 
Clayton) and a sociologist with experience in 
survey design (DR Morrison). The instrument 
used for the Peds cohort was designed by the 
same team. It was modified from the Adult 1 
cohort instrument to account for pediatric-
specific issues (i.e., the possibility that respon-
dents might view the collection of their child’s 
sample differently from the collection of their 
own sample) and based on feedback from the 
study personnel who fielded the Adult 1 cohort 
survey. Revisions incorporated into the design of 
the Adult 2 cohort instrument were intention-
ally minimized in order to facilitate comparisons 
with the earlier adult cohort. The Adult 2 cohort 
instrument was identical to the Adult 1 cohort 
with the exception of one additional question. As 
shown in Supplementary FigureS 2–4, all three instru-
ments were designed with branching logic; the 
questions asked of each participant were deter-
mined by his or her earlier responses. For this 
reason, several questions were posed to only a 
subset of respondents.
n Survey administration
All three cohorts were collected in clinical prac-
tice settings where information about the opt-
out biorepository was communicated through 
posters, pamphlets and consent-for-treatment 
forms. In order to increase the number of exit 
interviews conducted, interviewers coordinated 
with staff at each phlebotomy area to identify 
the periods each week when the most clinical 
blood samples were typically drawn. During 
these times, an interviewer was stationed outside 
the phlebotomy area and attempted to approach 
every patient (or pediatric patient’s parent) as 
they entered or exited the phlebotomy area. The 
interviewer identified qualified participants by 
asking “[Did you/will you] have your blood 
drawn today?” Only potential participants who 
answered affirmatively were invited to complete 
the survey. The interviewer explained that the 
survey would take about two minutes and would 
be completed anonymously. Interviewers also 
explained that respondents could choose to end 
the survey at any time.
Otherwise qualified patients were excluded 
from our study if they declined participation or 
were unable to complete the survey in English. 
In addition, when more than one patient entered 
or exited the phlebotomy area at the same time, 
the single interviewer was only able to approach 
one. Interviewers tallied the number of potential 
respondents who were not included in our study 
for each of these reasons. Potential respondents 
who exited the phlebotomy area at a time when 
the interviewer was busy were counted based on 
the observations of the interviewer; it is possible 
that some patients exited the phlebotomy area 
but were not noticed by the interviewer.
After obtaining agreement to participate, 
interviewers verbally administered the survey 
and recorded participant responses. As dem-
onstrated on the provided interview guides 
(Supplementary FigureS 2–4), some questions required 
interviewers to code open-ended participant 
responses. Interviews with adult patients 
included the collection of participant demo-
graphics, including age, gender and self-iden-
tified ethnicity. Interviews with the parents of 
pediatric patients involved collection of demo-
graphics for both the adult participant and the 
child having his or her blood drawn.
n Statistical ana lysis
The primary outcomes for this study were:
 Awareness of the Vanderbilt DNA databank;
 Awareness that leftover blood could be used 
for research;
 Support for the biorepository. 
An ana lysis of the two adult groups (Adult 1 
cohort vs Adult 2 cohort) allowed us to inves-
tigate changes over time. Inclusion of the Peds 
cohort allowed us to explore whether differences 
existed between adult patients and parents of 
pediatric patients. Initially, chi-squared tech-
niques were used to test for differences in gender 
and ethnicity between the two adult groups in 
order to reveal potential confounders for changes 
over time; an independent samples t-test was per-
formed to test for differences in age. Similarly, 
c2 and analysis of variance techniques were used 
to test whether parents of pediatric patients dif-
fered from the two adult groups. c2 techniques 
were used to test whether surveyed participants 
differed significantly in age, gender or ethnicity 
from the total patient population being seen in 
the medical center during that time period.
c2 techniques were used to test (unadjusted) 
for differences in the proportions of individuals 
in each group who:
 Had heard of the Vanderbilt DNA databank;
 Understood that leftover blood could be used 
for research;
 Supported the DNA databank.
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Similarly, c2 techniques were used to test 
for differences in the proportion of adults who 
recalled or preferred to opt-out of the DNA data-
bank between the two time points. Multivariable 
logistic regression techniques were used to test 
(adjusted for age, ethnicity and gender) whether 
inclusion in the Adult 1, Adult 2 and Peds 
cohorts predicted responses to questions related 
to the four primary outcomes. We performed a 
descriptive ana lysis of the reasons patients and 
parents of pediatric patients gave for supporting 
or opposing the DNA databank.
Results
n Demographics & participation rates
Our adult participants at Adult time point 1 
were significantly more likely to be black com-
pared with the total population of adult out-
patients seen in 2009 (19.5 vs 7.3%; p < 0.001). 
The adult cohort interviewed at Adult time point 
2 was significantly more likely to be white (87.5 
vs 61.9%; p < 0.001) when compared with the 
total population of adult patients seen in 2011 
and 2012 (table 1). Mean age differed signifi-
cantly between the two adult cohorts (57.8 vs 
52.1 years; p = 0.038). Respondents in adult 2 
cohort were significantly less likely to be black 
(19.5 vs 6.3%; p = 0.010) and significantly less 
likely to be other (2.6 vs 6.3%; p < 0.001) when 
compared with adult 1 cohort (table 1).
As expected, parents of pediatric patients 
who we interviewed were significantly different 
from adult patient participants. Parents were 
significantly more likely to be female (83.8 vs 
58.4% and 55.0%; p < 0.001), younger (29.3 vs 
57.8 years and 52.1 years; p < 0.001) and more 
likely to be a member of a minority racial/ethnic 
group (41.2 vs 22.1% and 12.5%; p < 0.001). 
The children whose parents were interviewed 
for our study were fairly representative of all 
pediatric patients seen in outpatient areas of the 
children’s hospital, with the exception of age; the 
children of respondents were younger compared 
with the general pediatric patient population 
(p < 0.001) (table 2). 
As a result of differences in patient popula-
tions, parents of pediatric patients were more 
likely to be unable to participate because they 
were non-English speaking compared with adult 
patients (tableS 3 & 4). In addition, more potential 
participants refused participation in the Adult 
2 cohort as compared with the other cohorts. 
Overall response rates were robust across all 
three cohorts (>60%).
nPrimary outcomes
Unadjusted, as seen in table 5, respondents in 
the Peds (18.8 vs 48.1% and 32.5%; p < 0.001) 
and Adult 2 cohorts (32.5 vs 48.1%; p = 0.047) 
were significantly less likely to have heard of the 
DNA databank. On the other hand, respondents 
in the Adult 1 cohort were significantly less likely 
to understand that leftover biospecimens could 
be used for research (34.3 vs 50.0% and 46.3%; 
p = 0.040).
Despite relatively low awareness, a large major-
ity of all three cohorts supported the DNA data-
bank after a brief explanation (n = 219, 92.5%), 
and parents of pediatric patients supported a 
DNA databank for children (n = 71, 88.8%).
As seen in table 6, the logistic regres-
sion models fit the data well, as indicated by 
Hosmer–Lemeshow p-values greater than 0.05. 
Following adjustment, adult patients at Adult 
time point 2 remained significantly more likely 
to recall signing a consent for treatment form 
(overall response [OR]: 2.10; 95% CI: 1.02–
4.32; p = 0.042) and to understand that their 
leftover specimens could be used for research 
(OR: 1.91; 95% CI: 1.07–3.73; p = 0.041) when 
compared with adult patients at Adult time point 
1. The decrease from Adult time point 1 to Adult 
Table 1. Adult demographics stratified by time point.
Demographic Adult 1 
cohort



















Adult 1 versus 
2 cohort
Female 45 (58.4) 128,085 (57.6) 0.884 44 (55) 119,356 (57.5) 0.654 0.664
Ethnicity White 60 (77.9) 155,339 (69.9) 0.124 70 (87.5) 128,442 (61.9) <0.001* 0.112
Black 15 (19.5) 16,291 (7.3) <0.001* 5 (6.3) 15,274 (7.4) 0.705 0.010*
Other 2 (2.6) 50,674 (22.8) <0.001* 5 (6.3) 63,930 (30.7) <0.001* <0.001*
Age (SD) 57.8 (1.74) 65.0 (0.91) 0.095 52.1 (1.64) 52.1 (0.88) 0.914 0.038*
*Significant at the 0.05 level. 
SD: Standard deviation.
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time point 2 in the proportion of respondents 
who reported having heard of the DNA data-
bank remained following adjustment (OR: 0.51; 
95% CI: 0.26–1.01; p = 0.054), although this 
change became nonsignificant. Females were 
more likely to have heard of the DNA databank 
(OR = 2.34; 95% CI: 1.23–4.44; p = 0.009) and 
older individuals were more likely to support the 
DNA databank (OR: 1.10; 95% CI: 1.02–1.18; 
p = 0.016). 
As seen in table 7, the most common reason 
provided by adult patients for supporting the 
biorepository was the potential for it to support 
research that improves understanding of diseases 
(coded by interviewers as “doctors will study dis-
eases”). As seen in table 8, parents of pediatric 
patients most often reported the potential for the 
biorepository to benefit others as a reason that 
they support the biorepository. Among those 
respondents who reported that they oppose the 
biorepository, two out of seven adult patients and 
two out of four parents of pediatric patients cited 
privacy concerns. 
Discussion
n Awareness of the DNA databank 
& use of leftover blood for research
We found that adult patients surveyed in 2009 
were more likely to report having heard of the 
DNA databank in comparison to adult patients 
surveyed from 2011 to 2012 (48.1 and 32.5%, 
respectively), even though awareness that left-
over blood could be used for research increased 
during this period, from 34.3 to 50.0%. We 
theorize that even though patients were increas-
ingly aware that leftover blood could be used for 
research, they became less likely to recognize the 
name ‘DNA databank’, in part because program 
literature increasingly used the name ‘BioVU’ to 
describe this resource. However, convenience-
based samples in pragmatic settings are sensitive 
to a range of procedures throughout a program. 
Thus, our data are best suited to provide both 
a benchmark and tracking for key measures, 
such as awareness and perceptions of the biore-
pository. This methodology does not facilitate 
attribution of trends to specific causes.
Although patients may not have been able to 
recognize that ‘DNA databank’ and ‘BioVU’ 
refer to the same research resource, the concept 
that leftover blood could be used for research is 
a consistent concept across all patient notifica-
tion efforts. For this reason, we believe it is the 
more accurate surrogate for awareness of this 
program. In an earlier study, we demonstrated 
that only 32% of patients recalled seeing post-
ers intended to notify them about BioVU [13]. 
Based on these data, notification efforts were 
Table 2. Demographic variables of pediatric patients whose parents participated in our study in comparison 
with all pediatric patients with outpatient visits during the study period.
Demographic Peds cohort (n = 80) (%) All pediatric outpatients 
(n = 63,199) (%)
p‑value
Age of child (SD) 4.4 (0.53) 8.04 (5.31) <0.001*
Female (child) 36 (45.0) 29,782 (47.1) 0.704
Child ethnicity White 45 (56.3) 30,806 (48.7) 0.180
Black 19 (23.8) 8309 (13.1) 0.005*
Other 16 (20.0) 24,084 (38.2) 0.001*
Location Multispecialty clinic 32 (40.0) – –
Primary care clinic 48 (60.0) – –
*Significant at the 0.05 level. 
Peds cohort: Pediatric cohort; SD: Standard deviation.
Table 3. Reasons for noninclusion.
Cohort Reason for noninclusion 
Patient/parent 
refused, n (%)
Staff busy, n (%) Non-English 
speaking, n (%)
Adult 1 (n = 35) 17 (48.6) 17 (48.6) 1 (3.8)
Adult 2 (n = 48) 34 (70.8) 14 (29.2) 0 (0.0)
Peds (n = 35) 8 (22.9) 4 (11.5) 23 (65.6)
Peds: Pediatric.
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markedly expanded, including handing pam-
phlets to all new patients, expanding posters to 
both phlebotomy and clinic areas and placing 
advertisements in local publications. Based on 
the findings of this study, these efforts seem to 
have been somewhat successful.
Although this increase in awareness is heart-
ening, it is not clear what an appropriate goal 
should be for this value. Even research partici-
pants who complete an informed consent process 
are not always aware that they are engaged in 
research. The percentage of participants in prior 
studies who are able to correctly identify that 
they are participating in research ranges from 
56.4 to 92.2% [14–18]. Even those who recog-
nize that they consented to research often do 
not recall the aims of that research; the propor-
tion who do ranges from 33.3 to 55.2% [14,19]. 
Despite these findings, at least one study has 
indicated that as much as 100% of bioreposi-
tory participants are able to identify this activity 
as research [20]. 
By comparing these previous findings with the 
results reported here, we believe that the opt-out 
procedures utilized by BioVU are not yet opti-
mal. Informed by these data and due to unrelated 
institutional interest in improving the quality of 
the outpatient consent to receive treatment pro-
cess, the entire medical center is currently tran-
sitioning from the paper-based process described 
above to a kiosk-based consent process. Instead 
of signing a two-page paper form every twelve 
months, patients will now be asked to acknowl-
edge each screen of information one-at-a-time. 
This includes a dedicated screen that includes 
a description of BioVU using language that has 
been rewritten for clarity and simplicity. The 
new language used in the kiosk-based consent is 
provided in Supplementary Figure 1b. We hypothesize 
that, since this new process requires an explicit 
acknowledgement from patients that they have 
read the presented information, patient aware-
ness of BioVU will improve.
We have also implemented ongoing exit 
interviews with patients based on the methods 
described in this report. These interviews will 
provide critical information in ongoing quality 
assurance efforts and will allow evaluation of 
whether the expanded notification methods will 
result in a higher level of awareness among our 
patient population.
n Approval of the opt-out approach to 
biobanking
Following a description of the biorepository, the 
vast majority of respondents report approval for 
this approach to sample collection for research 
on human health. This finding has been remark-
ably consistent across a range of populations and 
survey approaches. We recently reported on 
Table 5. Outcomes studied stratified by cohort.
Variable Adult 1 
cohort
(n = 77) (%) 
Adult 2 
cohort
(n = 80) (%)
p‑value Adult 2 
vs Adult 1 
cohort
Peds cohort
(n = 80) (%)
p‑value
Peds vs Adult 1 
& 2 cohorts
Previously heard of DNA databank 37 (48.1) 26 (32.5) 0.047* 15 (18.8) <0.001*
Understood leftover specimens could be used 
for research
25 (34.3) 40 (50.0) 0.026* 37 (46.3) 0.475
Recall previously choosing to opt-out of the 
DNA databank
2 (2.6) 2 (2.5) 0.969 – –
Support DNA databank 68 (88.3) 76 (95.0) 0.129 75 (93.8) 0.245
Support DNA databank for children – – – 71 (88.8) –
*Significant at the 0.05 level. 
Peds cohort: Pediatric cohort. 
Table 4. Response rates.
Cohort Total potential respondents (included and not included)
Response rate† (%) Refusal rate† (%)
Adult 1 (n = 112) 68.8 15.2
Adult 2 (n = 128) 62.5 26.6
Peds (n = 115) 69.6 7.0
†Rates are calculated according to the American Association for Public Opinion Research guidelines and assume that all 
nonparticipants would have been eligible [23]. 
Peds: Pediatric.
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large-scale surveys with members of the Nash-
ville community and employees of Vanderbilt 
University  (TN, USA) demonstrating rates of 
approval (93.9 and 94.6%, respectively) nearly 
identical to those identified in this study [21]. 
Although we did interview a small number of 
adult patients who reported previously opting 
out of BioVU (2.5%) and a small number who 
opposed the biobank (7.6%), this sample was 
inadequate to conclusively identify the reasons 
that usually motivate this decision.
n Voluntariness of participation
We believe there are at least three empirical 
questions relevant to assessing whether the opt-
out approach to building biorepositories can 
effectively ensure that inclusion of biosamples 
is voluntary:
 Are patients made aware of the research 
through notification efforts and the opt-out 
form? 
 Are patients provided with enough information 
to make an effective decision?
 Are patients aware of not only the research, 
but also of their opportunity to opt-out?
The present study addresses only the first 
empirical question, although our answer is an 
incomplete one. Even though we were able to 
determine that roughly half of patients report 
that they are not aware that their leftover blood 
could be used for research, we are not able to 
discriminate among the possible explanations for 
this finding. It is likely that some patients have 
simply never noticed the posters in clinic areas, 




Predictor OR 95% CI of OR p‑value
Recognize consent for 
treatment form (p = 0.575)
Adult 1 cohort Ref. – –
Adult 2 cohort 2.10 1.02–4.32 0.042*
Peds cohort 1.68 0.69–4.10 0.178
White 0.67 0.35–1.31 0.676
Female 1.03 0.55–1.91 0.931
Age 1.00 0.98–1.02 0.963
Have heard of DNA 
databank (p = 0.635)
Adult 1 cohort Ref. – –
Adult 2 cohort 0.51 0.26–1.01 0.054
Peds cohort 0.21 0.08–0.51 0.001*
White 1.15 0.57–2.35 0.692
Female 2.34 1.23–4.44 0.009*
Age 1.00 0.98–1.02 0.953
Understand leftover blood 
could be used for research 
(p = 0.125)
Adult 1 cohort Ref. – –
Adult 2 cohort 1.91 1.07–3.73 0.041*
Peds cohort 1.10 0.48–2.50 0.821
White 1.08 0.57–2.04 0.822
Female 1.76 0.97–3.18 0.061
Age 0.99 0.97–1.01 0.248
Support DNA databank 
(p = 0.875)
Adult 1 cohort Ref. – –
Adult 2 cohort 2.44 0.74–8.53 0.147
Peds cohort 2.25 0.72–7.32 0.204
White 2.08 0.58–3.62 0.182
Female 1.60 0.48–2.57 0.697
Age 1.10 1.02–1.18 0.016*
A Hosmer–Lemeshow p-value greater than 0.05 suggests the model fits the data well.
*Significant at the 0.05 level. 
OR: Overall response; Peds cohort: Pediatric cohort; Ref.: Reference.
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pamphlets handed out in clinics and opt-out 
language included on the consent for treatment 
form. Other patients may have seen one or more 
of these notifications, but did not understand its 
content. These are the causes that we are most 
interested in eliminating, since they are particu-
larly relevant to the question of voluntariness of 
inclusion in BioVU. However, there are certainly 
other possible reasons that patients report not 
being aware of the DNA databank. For example, 
previous research on participant recall in the 
setting of informed consent to research partici-
pation, as described above, indicates that even 
individuals who undergo a detailed informed 
consent process do not recall the key elements 
of that information.
Indeed, our results indicate that even though 
we can assume that every patient has signed a 
consent for treatment form in the past and there-
fore has had an opportunity to read information 
pertaining to BioVU (since medical center poli-
cies require that a signed copy of the consent for 
treatment form must be in the electronic medi-
cal record in order for an outpatient to receive 
treatment), 23.8% of parents either report that 
they have never seen the form or that they are 
not sure whether they have seen the form. Since 
we do not have access to respondents’ adminis-
trative records, we are unable to infer what has 
caused this lack of recall (i.e., parents who signed 
these forms recently yet report they have never 
seen them may not have been attentive to what 
they were signing; parents who signed the forms 
months ago may have just forgotten about them).
However, it does appear that recognition of the 
form is a relatively strong predictor of awareness 
that leftover blood could be used for research; 
those patients who report signing the consent for 
treatment form on the day they responded to the 
survey are significantly more likely to be aware 
that leftover blood could be used for research 
compared with those who do not recall signing 
the form (61 vs 37%; p = 0.0007).
Limitations
This study has a number of limitations, several of 
which have been mentioned above. Perhaps the 
most significant limitation of this study is that 
all variables are based on patient recall. We did 
not seek permission from respondents to access 
their administrative records, so we do not know 
which of them had opted out of the biorepository 
Table 8. Reasons given by parents of pediatric patients for supporting or opposing 
including children in the DNA databank.
Response Number of respondents (%)
Reasons for supporting†:
Benefit other people
Benefit me or my family
Benefit people with same disease 







Concerned about privacy of DNA information






†Respondents were permitted to provide multiple reasons.
Table 7. Reasons given by adult patients for supporting or opposing the DNA 
databank.
Response Number of respondents (%)
Adult 1 cohort Adult 2 cohort
Reasons for supporting†:
Research might benefit me or my family
Research is being done at Vanderbilt
Collection of samples is helpful to scientists















I do not know how my DNA will be used










†Respondents were permitted to provide multiple reasons.
Personalized Medicine (2013) 10 (4)356 future science group
Patient awareness & approval for an opt-out genomic biorepository ReseaRch aRticle
in the past or when each last viewed and signed 
the ‘consent for treatment’ form. We also do 
not know who is actually included in the bio-
repository, since all data in the biorepository is 
de-identified.
An additional limitation is that all three 
cohorts were collected as convenience samples. 
In order to maximize the number of patients 
who could be surveyed, interviewers focused on 
the busiest phlebotomy areas on their busiest 
days of the week. However, all four of the phle-
botomy areas where patients were interviewed 
(two adult, two pediatric) serve multiple clin-
ics. One of the pediatric locations and one of 
the adult locations serve primarily subspecialty 
clinics, while the remaining two locations serve 
primarily primary care patients. Interviewers 
were intentional in balancing interviews con-
ducted at each location. We have assessed selec-
tion bias in two ways: by tallying the patients 
who were not included in our study (tableS 3 & 4) 
and by comparing our sample with the total 
outpatient population (tableS 1 & 2). The former 
method indicates a strong response rate for this 
survey and the latter method demonstrates that 
our sample is reasonably representative of the 
patient population of interest.
The absence of comparison groups also signifi-
cantly limits our ability to interpret the findings 
of this study. We have identified only one previous 
study evaluating awareness of an ongoing research 
project involving an opt-out dimension, although 
the research involved – a study of resuscitation 
algorithms in a pediatric intensive care unit – is 
significantly different from that performed using 
a genomic biorepository [22]. As other institu-
tions develop bio repositories based on opt-in and 
opt-out models, patient awareness and approval 
should be evaluated. This experience across set-
tings will help establish best practices for patient 
notification and meaningful benchmarks for 
awareness of opt-in and opt-out approaches to 
biorepository research.
Conclusion
We found that many patients and parents of pedi-
atric patients having blood drawn as a part of their 
medical care were not aware of our opt-out bio-
repository that collects leftover clinical samples to 
be used for research on health, although the vast 
majority approved of this research effort. While 
recognition of the ‘DNA databank’ decreased over 
time among adult patients, awareness that leftover 
blood could be used for research increased. We 
attribute this increase to ongoing patient notifi-
cation efforts, although the relatively low level 
of awareness in our sample indicates that addi-
tional improvements in these efforts are needed. 
Additional empirical research will be needed to 
inform a thorough ana lysis of the suitability of 
opt-out methods to ensure voluntary participation 
in research.
Future perspective
In future work we hope to conduct interviews with 
patients who have given us consent to access their 
electronic administrative record. This approach 
will not only allow us to assess whether patients 
who recently signed consent for treatment forms 
are more likely to be aware of BioVU, but also 
to assess whether patients who report a desire to 
opt-out of inclusion have successfully opted out 
in the past. These additional data will help us 
address our overarching aim of examining the 
effectiveness of opt-out procedures for ensuring 
voluntary participation in research.
We hope other biorepositories utilizing opt-
out and opt-in methods will conduct similar 
empirical research in their own research settings. 
These new empirical findings will help inform 
the follow-on ethical and policy ana lysis that 
will be needed to determine the appropriateness 
of opt-in and opt-out methods, since, in certain 
circumstances, traditional informed consent can 
be impractical or can pose a significant barrier to 
answering important research questions.
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